Ingelheim, Germany Illustrative photo In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in…

Read More

Editor' Pick

Canada News

Lifestyle

Tech & Innovation

Latest News